The Montreal Classification of Inflammatory Bowel Disease: Controversies, Consensus, and Implications

Overview

Journal Gut

Specialty Gastroenterology

Date 2006 May 16

PMID 16698746

Citations 1121

Authors

J Satsangi

M S Silverberg

S Vermeire

J-F Colombel

Affiliations

Soon will be listed here.

Abstract

In recent years, investigators have readdressed the complex issues involved in the classification of inflammatory bowel diseases. In 2003, a Working Party of investigators with an interest in the issues involved in disease subclassification was formed with the aim of summarising recent developments in disease classification and establishing an integrated clinical, molecular, and serological classification of inflammatory bowel disease. The results of the Working Party were reported at the 2005 Montreal World Congress of Gastroenterology. Here we highlight the key issues that have emerged from discussions of the Montreal Working Party and the relevance to clinical practice and research activities.

Citing Articles

Genetic Polymorphisms (ApaI, FokI, BsmI, and TaqI) of the Vitamin D Receptor (VDR) Influence the Natural History and Phenotype of Crohn's Disease.

Kafentzi T, Tsounis E, Tourkochristou E, Avramopoulou E, Aggeletopoulou I, Geramoutsos G Int J Mol Sci. 2025; 26(5).

PMID: 40076474 PMC: 11899612. DOI: 10.3390/ijms26051848.

Temporal Trends in the Use of Biological Agents in Patients with Inflammatory Bowel Disease: Real-World Data from a Tertiary Inflammatory Bowel Disease Greek Center During a 5-Year Period.

Markopoulos P, Gaki A, Kokkotis G, Chalakatevaki K, Kioulos N, Kitsou V J Clin Med. 2025; 14(4).

PMID: 40004889 PMC: 11856159. DOI: 10.3390/jcm14041357.

Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment.

Atay A, Cagir Y, Ergul M, Ozturk O, Durak M, Yuksel I J Clin Med. 2025; 14(4).

PMID: 40004757 PMC: 11857063. DOI: 10.3390/jcm14041228.

Immunohistochemistry Analysis in Inflammatory Bowel Disease-Should We Bring to Light Interleukin-10?.

Pavel C, Diculescu M, Ilie M, Plotogea O, Sandru V, Enache V Biomedicines. 2025; 13(2).

PMID: 40002819 PMC: 11853417. DOI: 10.3390/biomedicines13020406.

Adiponectin and HMW Oligomers in Relation to Inflammatory Markers in Crohn's Disease Patients.

Marra M, Mallardo M, Nigro E, Cioffi I, Leo C, Guarino A Biomedicines. 2025; 13(2).

PMID: 40002687 PMC: 11853605. DOI: 10.3390/biomedicines13020273.

References

Bairead E, Harmon D, Curtis A, Kelly Y, OLeary C, Gardner M . Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur J Hum Genet. 2003; 11(3):237-44. DOI: 10.1038/sj.ejhg.5200954. View

Targan S, Landers C, Yang H, Lodes M, Cong Y, Papadakis K . Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005; 128(7):2020-8. DOI: 10.1053/j.gastro.2005.03.046. View

Russell R, Drummond H, Nimmo E, Anderson N, Smith L, Wilson D . Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis. 2005; 11(11):955-64. DOI: 10.1097/01.mib.0000183423.38037.f3. View

Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall S, Orchard T . The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002; 122(4):854-66. DOI: 10.1053/gast.2002.32413. View

Louis E, Collard A, Oger A, Degroote E, Aboul Nasr El Yafi F, Belaiche J . Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49(6):777-82. PMC: 1728556. DOI: 10.1136/gut.49.6.777. View

Brant S, Panhuysen C, Bailey-Wilson J, Rohal P, Lee S, Mann J . Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology. 2000; 119(6):1483-90. DOI: 10.1053/gast.2000.20245. View

Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein C, Brant S . Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 Suppl A:5A-36A. DOI: 10.1155/2005/269076. View

Economou M, Trikalinos T, Loizou K, Tsianos E, Ioannidis J . Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004; 99(12):2393-404. DOI: 10.1111/j.1572-0241.2004.40304.x. View

Gasche C, Scholmerich J, Brynskov J, DHaens G, Hanauer S, Irvine E . A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000; 6(1):8-15. DOI: 10.1097/00054725-200002000-00002. View

10.

Abreu M, Taylor K, Lin Y, Hang T, Gaiennie J, Landers C . Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002; 123(3):679-88. DOI: 10.1053/gast.2002.35393. View

11.

Langholz E, Munkholm P, Davidsen M, Binder V . Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994; 107(1):3-11. DOI: 10.1016/0016-5085(94)90054-x. View

12.

Mow W, Vasiliauskas E, Lin Y, Fleshner P, Papadakis K, Taylor K . Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004; 126(2):414-24. DOI: 10.1053/j.gastro.2003.11.015. View

13.

Arnott I, Nimmo E, Drummond H, Fennell J, Smith B, MacKinlay E . NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?. Genes Immun. 2004; 5(5):417-25. DOI: 10.1038/sj.gene.6364111. View

14.

Arnott I, Landers C, Nimmo E, Drummond H, Smith B, Targan S . Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004; 99(12):2376-84. DOI: 10.1111/j.1572-0241.2004.40417.x. View

15.

Vasiliauskas E, Kam L, Karp L, Gaiennie J, Yang H, Targan S . Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000; 47(4):487-96. PMC: 1728065. DOI: 10.1136/gut.47.4.487. View

16.

Price A . Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'. J Clin Pathol. 1978; 31(6):567-77. PMC: 1145346. DOI: 10.1136/jcp.31.6.567. View

17.

Ho G, Nimmo E, Tenesa A, Fennell J, Drummond H, Mowat C . Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005; 128(2):288-96. DOI: 10.1053/j.gastro.2004.11.019. View

18.

Rioux J, Silverberg M, Daly M, Steinhart A, McLeod R, Griffiths A . Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet. 2000; 66(6):1863-70. PMC: 1378042. DOI: 10.1086/302913. View

19.

Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M . The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002; 122(5):1242-7. DOI: 10.1053/gast.2002.32980. View

20.

Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y . Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology. 2002; 123(1):86-91. DOI: 10.1053/gast.2002.34155. View